VB10-NEO(Vaccibody AS) Drug Asset Due Diligence Report 2026

This VB10-NEO(Vaccibody AS) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether VB10-NEO(Vaccibody AS) can convert its Personalized antigen vaccine, Therapeutic vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	VB10-NEO(Vaccibody AS) (query alias: VB10-NEO(Vaccibody AS))
Modality / target	Personalized antigen vaccine, Therapeutic vaccine; Not disclosed; Immunostimulants
Highest global status	Phase 2
Originator	Nykode Therapeutics ASA
Active developers	Genentech, Inc., Nykode Therapeutics ASA

The MCP disease footprint includes Bladder Cancer, Head and Neck Neoplasms, Melanoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05018273	Phase 1	Completed	26	Primary endpoint not disclosed in English source
NCT03548467	Phase 1/2	Completed	41	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

117 Integrative analyses of multiomics data and biomarker readout demonstrate clinical and immunological relevance of individualized vaccine design via the NeoSELECT™ platform | Journal for ImmunoTherapy of Cancer

Phase 1/2; n=46; evaluation: Positive. Reported fields: T cell response = 94.0 % ; T cell response = 100.0 %

Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.

Phase 1; n=26; evaluation: Positive. Reported fields: Adverse Event: Grade 3 transient blood pressure increase = A dose-limiting Grade 3 transient blood pressure increase occurred in the 9 mg cohort

Abstract CT274: Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial

Phase 1/2; n=41; evaluation: Positive. Reported fields: Safety = safe and well-tolerated with no new or additional toxicity

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

VB10-NEO(Vaccibody AS) addresses Bladder Cancer, Head and Neck Neoplasms, Melanoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Personalized antigen vaccine, Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-11-12	Roche hands back cancer vaccine rights to Nykode	Phase 1/2	US$200.0M upfront; US$515.0M milestones
2018-09-20	VACCIBODY ANNOUNCES CLINICAL COLLABORATION AGREEMENT WITH NEKTAR THERAPEUTICS FOR EVALUATION OF VACCIBODY’S PERSONALIZED CANCER NEOANTIGEN VACCINE IN COMBINATION WITH NEKTAR’S CD-122-BIASED AGONIST, NKTR-214	Phase 1/2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Betacoronavirus prophylaxis and therapy”. The milestone feed surfaced a patent-application signal described as “Therapeutic anticancer neoepitope vaccine”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO